StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Saturday morning. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald restated an overweight rating and issued a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Stock Performance

NYSE VNRX opened at $0.63 on Friday. The stock has a 50-day simple moving average of $0.74 and a two-hundred day simple moving average of $0.84. The firm has a market capitalization of $52.25 million, a P/E ratio of -1.37 and a beta of 1.14. VolitionRx has a fifty-two week low of $0.55 and a fifty-two week high of $1.55.

VolitionRx (NYSE:VNRX) last released its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. As a group, analysts forecast that VolitionRx will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC acquired a new position in VolitionRx Limited (NYSE:VNRX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned about 0.19% of VolitionRx at the end of the most recent quarter. Institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.